Global Ophthalmic Drugs Market industry valued approximately USD 23.21 billion in 2016 is anticipated to grow with a healthy growth rate of more than 5.27% over the forecast period 2017-2025. Rising frequencies of eye disorders like macular degeneration, presbyopia, and diabetic retinopathy among the most prevalent age groups are speculated to propel the growth.
The objective of the study is to define market sizes of different segments & countries in previous years and to forecast the values to the next eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as drivers & restraining factors which will define the future growth of the market. Additionally, it will also incorporate the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
Disease Type:
§ Dry Eye Drugs
§ Retinal Disorders Drugs
§ Ophthalmic Anti-Allergy/Inflammatory/Infective Drugs
§ Anti-Glaucoma Drugs
Delivery Type:
§ Capsules & Tablets
§ Gels
§ Eye Drops
§ Eye Ointment
§ Eye Solutions
Product Type:
§ Prescription Drugs
§ Over-the-Counter Drugs
Regions:
§ North America
o U.S.
o Canada
§ Europe
o UK
o Germany
§ Asia Pacific
o China
o India
o Japan
§ Latin America
o Brazil
o Mexico
§ Rest of the World
Furthermore, the years considered for the study are as follows:
Historical year – 2015
Base year – 2016
Forecast period – 2017 to 2025
Some of the key manufacturers involved in the market are Valeant Pharmaceuticals International, Inc., Sun Pharmaceutical Industries Ltd, Shire Plc, Regeneron Pharmaceuticals, Inc., Alcon, Pfizer Inc., Genentech, Inc., and Santen Pharmaceutical Co., Ltd. New product launches, acquisitions & effective mergers and focuses on continuous technology innovations are some of the strategies adopted by the key manufacturers. The companies are also trying to dominate the market by investing in research and development.
Target Audience of the Ophthalmic Drugs Market Study
§ Key Consulting Companies & Advisors
§ Large, medium-sized, and small enterprises
§ Venture capitalists
§ Value-Added Resellers (VARs)
§ Third-party knowledge providers
§ Investment bankers
§ Investors
